Monsanto's GMO Seeds May No Longer Be Invincible

A lawsuit in Australia could pose a threat to the biotech's genetically modified seed empire.

Feb 13, 2014 at 2:00PM

Ever since the introduction of genetically modified crops into the food chain, the tussle has been largely between farmers and Monsanto (NYSE:MON), which says since 1997 it has filed 145 lawsuits against farmers who've improperly reused its patented seeds, or on average about one lawsuit every three weeks for 16 straight years.


Canola field. Source:

In that time frame, the biotech hasn't lost a single case, even when farmers like the organic growers who had their case against Monsanto tossed last year sued for cross-contamination of their crops. DuPont (NYSE:DD), the world's second-largest seed producer behind Monsanto, is similarly seeking to police the use of its seeds by hiring retired police officers to ferret out farmers allegedly improperly using its patented seeds. Defeating the well-financed GMO behemoth has been a losing battle, but that may be about to change.

In 2010, a western Australia organic farmer, Steve Marsh, found that his harvest had been contaminated by his neighbor's genetically modified canola/rapeseed crops planted with Monsanto Roundup Ready seed. Marsh subsequently had 70% of his farm's organic status for produce stripped from him causing severe financial harm, some $85,000 in earnings. In a first of its kind lawsuit, Marsh is suing his neighbor for the loss resulting from the seeds blowing onto his oat and wheat crop, contaminating them.

The significance of the case is that if Marsh can successful defend his property rights, it will create a disincentive for farmers to use GM seeds if they know they will be held liable for the equivalent of "polluting" a neighbor's property. Just as a company can be held liable for toxic runoff that contaminates an adjacent piece of land, this lawsuit seeks to hold GM farmers liable for their "runoff" that ruins a neighbor's livelihood.

But the lawsuit could cut both ways if successful, because it may cause Australia to relax its otherwise-strict zero-tolerance policy toward GM produce. Unlike the U.S. and elsewhere where the probability of cross-contamination is acknowledged and trace amounts of GMOs are permitted in crops that are otherwise labeled "organic," Australia doesn't have that distinction. Organic means 100% organic with no trace GMOs permitted, and that might change in a bid to allow peaceful coexistence. But if Marsh loses the case, then GM farmers and Monsanto can rest easy knowing they'll be able to plant their lab-altered seed without consequence.

Monsanto, DuPont, and Syngenta (NYSE:SYT) control 53% of the world's seed production with their GM variants. Virtually all alfalfa, corn, soybean, and sugar beet seed are genetically modified, and because of their widespread use in processed foods, it means anywhere from 60% to 70% of all food on supermarket shelves is genetically modified. Dupont and Syngenta have teamed up with Dow Chemical (NYSE:DOW) to fight a new law in Hawaii that prohibits the planting of new GM crops on the big island. 

The Australian farmer Marsh regained his organic certification last November following his neighbor agreeing to modify his harvesting methods to minimize the opportunity for his GM seeds to cross contaminate adjacent properties. Unfortunately for organic farmers not located in Australia, the tolerance for GMO traces in organic produce means they would have a steeper hill to climb, though perhaps on the basis of a property rights protection issue, it could be a wedge to sever the unrestrained proliferation of genetically modified seed.

Because Monsanto requires farmers to sign non-liability clauses when they purchase seeds from the biotech, it's insulated from being a party to the lawsuit directly, though it demurred when specifically asked whether it was providing financial assistance to the defense. But a win by Marsh could show there is indeed a chink in Monsanto's armor of invincibility.

Biotechs for positive change
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Rich Duprey has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information

Compare Brokers